Proto Labs Inc (PRLB) Stock Price & Analysis
Proto Labs Inc (PRLB) fell 0.87% to USD 75.48 as of June 10, 2026 at 01:55 UTC, according to Nexqual real-time market data.
PRLB last closed at USD 76.14; the session ranged USD 72.9–78.68 on volume of 191,635 shares. Market capitalization is $1.80B, with a 52-week range of USD 37.4–78.68 (NYQ). Source: Nexqual, June 10, 2026 at 01:55 UTC.
Key Statistics (as of June 10, 2026 at 01:55 UTC)
| Price | USD 75.48 |
|---|---|
| Change | ▼ 0.87% (down) |
| Previous Close | USD 76.14 |
| Open | USD 77.16 |
| Day Range | USD 72.9 – 78.68 |
| 52-Week Range | USD 37.4 – 78.68 |
| Volume | 191,635 shares |
| Market Cap | $1.80B |
| Exchange | NYQ |
Technical Analysis (PRLB)
Nexqual's technical model rates PRLB "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 01:55 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.33 (neutral) |
| vs SMA50 | Above (USD 67.2) |
| MACD | 2.34 (positive) |
Analyst Ratings (PRLB)
Wall Street analysts rate PRLB "Buy" based on 3 analysts, with a mean price target of USD 75.67 (range USD 70–82), per Nexqual as of June 10, 2026 at 01:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 75.67 |
| High Target | USD 82 |
| Low Target | USD 70 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (PRLB)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.54 |
| Revenue Estimate | $144.18M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.54 vs est 0.39 ▲ beat |
| 2025-12-31 | USD 0.44 vs est 0.34 ▲ beat |
| 2025-09-30 | USD 0.47 vs est 0.39 ▲ beat |
| 2025-06-30 | USD 0.41 vs est 0.34 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Financials & Fundamentals (PRLB)
| Total Revenue | $546.26M |
|---|---|
| Revenue Growth (YoY) | +10.40% |
| Gross Margin | +44.86% |
| Operating Margin | +8.08% |
| Profit Margin | +4.71% |
| ROE | +3.84% |
| Debt / Equity | 0.38 |
| Current Ratio | 3.52 |
| Total Cash | $136.28M |
| Total Debt | $2.62M |
| Free Cash Flow | $46.06M |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Financial Health Score (PRLB)
Nexqual rates Proto Labs Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:55 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 45%, operating 8% |
| Balance Sheet | Strong — $136M cash vs $3M debt, net cash position |
| Cash Flow | Solid — FCF $46M, 9% margin |
| Efficiency | Weak — ROE 4%, ROA 2.7% |
Ownership (PRLB)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +94.91% |
| Shares Outstanding | 23.79M |
| Float | 23.48M |
| Short % of Float | +3.72% |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
Leadership (PRLB)
Proto Labs Inc is led by Suresh Krishna (age 56), President, CEO & Director, per Nexqual as of June 10, 2026 at 01:55 UTC.
| President, CEO & Director | Suresh Krishna (age 56) |
|---|---|
| CFO and Principal Financial & Accounting Officer | Daniel Schumacher (age 50) |
| Chief Technology & AI Officer | Marc A. Kermisch (age 51) |
| Chief Marketing Officer | Brian F. Peters |
Major Backers & Investors (PRLB)
Notable institutional backers of Proto Labs Inc include Disciplined Growth Investors, Inc., American Capital Management, Inc., Renaissance Technologies, according to Nexqual as of June 10, 2026 at 01:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Disciplined Growth Investors, Inc. | 11.63% |
| American Capital Management, Inc. | 2.64% |
| Renaissance Technologies | 2.19% |
| Rubric Capital Management LP | 2.04% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 1.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.88% |
| Vanguard Group | 18.89% |
| State Street | 5.49% |
| Dimensional Fund Advisors | 5.35% |
| Geode Capital | 2.44% |
Source: Nexqual, June 10, 2026 at 01:55 UTC.
From Proto Labs Inc's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Since our inception, we have manufactured over 700 million parts, and served over 300,000 customers, including 95% of Fortune 100 companies in key industries.
- For most of our offerings, our proprietary technology eliminates most of the time-consuming and expensive skilled labor conventionally required to quote and manufacture parts.
- Our technology enables us to ship parts not only with industry-leading speed as soon as the same day after receipt of a customer's design submission, but also provides the flexibility to produce for our customers custom parts in the manufacturing processes and materials they want, with the flexible lead time they choose, at competitive prices. 6 Table of Contents Our primary manufacturing service lines are Injection Molding, CNC Machining, 3D Printing, and Sheet Metal.
- Using our technology, we have analyzed over 18 million unique part designs since inception.
Partnerships
- Our Growth Strategy We currently operate in a global custom contract manufacturing market which is a form of outsourcing where companies enter into an arrangement or formal agreement with another company or individual for the manufacture of complete parts, products, or components.
- Overtime is performed and compensated in accordance with applicable law and the terms of the individual's employment contract or other applicable contract or agreement. • Education We believe that investing in the education of our employees is critical to our success.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MTLS | Materialise NV | USD 6.63 | ▲ 1.07% |
| SSYS | Stratasys, Ltd. | USD 8.66 | ▼ 2.15% |
| DDD | 3D Systems Corporation | USD 2.95 | ▲ 1.37% |
| TREE | LendingTree, Inc. | USD 36.37 | ▲ 1.45% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:55 UTC. This page is informational and not investment advice.